1. Home
  2. JD vs NTRA Comparison

JD vs NTRA Comparison

Compare JD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JD.com Inc.

JD

JD.com Inc.

N/A

Current Price

$29.39

Market Cap

39.2B

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$331.64

Market Cap

45.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JD
NTRA
Founded
2006
2003
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2B
45.3B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
JD
NTRA
Price
$29.39
$331.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
15
Target Price
$39.27
$259.07
AVG Volume (30 Days)
9.0M
1.3M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
3.37%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$8.17
$18.08
Revenue Next Year
$6.01
$19.65
P/E Ratio
$9.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.51
$157.43
52 Week High
$36.86
$333.56

Technical Indicators

Market Signals
Indicator
JD
NTRA
Relative Strength Index (RSI) 43.23 71.73
Support Level $28.38 $187.64
Resistance Level $30.44 N/A
Average True Range (ATR) 0.68 10.88
MACD -0.44 2.40
Stochastic Oscillator 21.44 96.11

Price Performance

Historical Comparison
JD
NTRA

About JD JD.com Inc.

JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: